To elucidate the effects of scientific research performed within the Hospital District of Helsinki and Uusimaa (HUS) on the treatment of patients, we studied the contribution of HUS to treatment recommendation work, preparation of textbooks and manuals, national or international expert assignments, as well as by using focused questionnaires. In our surveys, 82% of the research group leaders reported that their research has resulted in changes in clinical work. The total number of changes was approximately 700. More than 80% of the directors of medical services judged that research work had improved the expertise of the personnel as well as the effectivity and productivity of the hospital.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Survey of legislative frameworks and national recommendations governing paediatric maintenance haemodialysis in Europe.
Pediatr Nephrol
January 2025
Centre de Référence des Maladies Rénales Rares, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, 59 boulevard Pinel, 69677, Bron Cedex, France.
Background: The application of international recommendations for paediatric maintenance haemodialysis (HD) could be strengthened by national laws or written recommendations. Our aim was therefore to describe the national rules governing paediatric maintenance HD in European countries.
Methods: A national representative, approved by the president of each paediatric nephrology society, was contacted in all 42 European countries to complete two online questionnaires.
Access to plasma viral load in people living with HIV under treatment in Ouagadougou and Bobo Dioulasso, Burkina Faso.
IJID Reg
March 2025
Department of Public Health, RTU/HS, University Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.
Objectives: Less than 25% of people living with HIV (PLWHIV) achieved plasma viral load (PVL) in 2020 in Burkina Faso. This study aimed to identify factors associated with access to PVL in Ouagadougou and Bobo-Dioulasso.
Methods: A cross-sectional analytical study was conducted among PLWHIV in Burkina Faso between April 15 and August 8, 2022.
A compound heterozygous mutation causes congenital thrombotic thrombocytopenic purpura: a case report.
Front Med (Lausanne)
January 2025
Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Congenital thrombotic thrombocytopenic purpura (cTTP) is a thrombotic microangiopathy (TMA) characterized by severe hereditary ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs 13) deficiency caused by mutations. This rare autosomal recessive genetic disorder is often misdiagnosed as immune thrombocytopenia (ITP) or hemolytic uremic syndrome (HUS). Here, we report a 21-year-old male cTTP patient with a compound heterozygous mutation.
View Article and Find Full Text PDFSynergistic combination of orally available safe-in-man pleconaril, AG7404, and mindeudesivir inhibits enterovirus infections in human cell and organoid cultures.
Cell Mol Life Sci
January 2025
Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, Trondheim, 7028, Norway.
Enteroviruses can infect various human organs, causing diseases such as meningitis, the common cold, hand-foot-and-mouth disease, myocarditis, pancreatitis, hepatitis, poliomyelitis, sepsis, and type 1 diabetes. Currently, there are no approved treatments for enterovirus infections. In this study, we identified a synergistic combination of orally available, safe-in-man pleconaril, AG7404, and mindeudesivir, that at non-toxic concentrations effectively inhibited enterovirus replication in human cell and organoid cultures.
View Article and Find Full Text PDFEfficacy of complement inhibition with pegcetacoplan in children with C3 glomerulopathy.
Pediatr Nephrol
January 2025
Center for HUS Prevention, Control and Management at the Pediatric Nephrology, Dialysis and Transplantation Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Background: C3 glomerulopathy (C3G) is a rare kidney disease due to a dysregulation of the alternative complement pathway, orphan of specific treatment. Pegcetacoplan is an inhibitor of the third complement component C3, currently on a phase III registration protocol in C3G. Here we describe our experience with the off-label use of pegcetacoplan in pediatric patients with C3G.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!